1. A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia
- Author
-
Mehmet Sönmez, Sevil Sadri, Vildan Ozkocaman, Hasan Atilla Ozkan, Levent Undar, Ahmet Muzaffer Demir, Olga Meltem Akay Yanar, Derya Selim Bapur, Anil Tombak, Erden Atilla, Volkan Karakuş, Pinar Tarkun, Güray Saydam, Inci Alacacioglu, Can Ozlu, Demet Çekdemir, Hasan Dermenci, Tülin Tuğlular Fıratlı, Demet Aydin, Eyup Naci Tiftik, Müzeyyen Aslaner, Ülkü Ozan, Sehmus Ertop, Ozan Salim, Muhit Ozcan, Tayfur Toptas, Sinan Demircioğlu, Noyan F, Gülsüm Özet, Abdullah Karakuş, Mehmet Ali Özcan, Güven Çetin, Funda Pepedil Tanrikulu, Zafer Gokgoz, Esra Ermiş Turak, Reyhan Diz Küçükkaya, Fusun Ozdemirkiran, Mehmet Turgut, Özkan Sayan, Mesut Ayer, Düzgün Özatlı, Melda Cömert, Neslihan Andic, Mehmet Özen, Pelin Aytan, Mustafa Nuri Yenerel, Oktay Bilgir, Guchan Alanoglu, Ali Ünal, Isik Kaygusuz Atagunduz, Ramazan Esen, Kadir Acar, Alev Akyol Erikçi, Serkan Güvenç, Mustafa Pehlivan, Cenk Sunu, Erman Öztürk, Fadime Ersoy Dursun, Ebru Kızılkılıç, Sinem Namdaroglu, Umit Yavuz Malkan, Burhan Turgut, Nevin Alayvaz, Mustafa Çetiner, Teoman Soysal, Vahap Aslan, Hatice Terzi, Murat Tombuloglu, Ali Eser, Kadriye Bahriye Payzın, Handan Haydaroglu Sahin, Mehmet Gunduz, Mehmet Sinan Dal, Funda Ceran, Orhan Ayyildiz, Emin Kaya, Mehmet Şencan, Ibrahim C. Haznedaroglu, Guven Yilmaz, Burak Deveci, Bahar Uncu Ulu, Ayhan Gulsan Turkoz Sucak, Demet Kiper, and Atakan Tekinalp
- Subjects
Agonist ,Thrombopoietin receptor ,medicine.medical_specialty ,Weakness ,medicine.drug_class ,business.industry ,Eltrombopag ,Retrospective cohort study ,Hematology ,030204 cardiovascular system & hematology ,medicine.disease ,Thrombosis ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Refractory ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Platelet ,medicine.symptom ,business - Abstract
Objective The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm3) and defined as complete (platelet count of >100,000/mm3), partial (30,000-100,000/mm3 or doubling of platelet count after treatment), or unresponsive (
- Published
- 2019
- Full Text
- View/download PDF